NARIRUTIN INHIBITS AIRWAY INFLAMMATION IN AN ALLERGIC MOUSE MODEL

• Published in: Clinical and experimental pharmacology & physiology Vol. 34; no. 8; pp. 766 - 770
• Main Authors: Funaguchi, Norihiko, Ohno, Yasushi, La, Bu Lin Bai, Asai, Toshihiro, Yuhgetsu, Hideyuki, Sawada, Masahiro, Takemura, Genzou, Minatoguchi, Shinya, Fujiwara, Takako, Fujiwara, Hisayoshi
• Format: Journal Article
• Language: English
• Published: Melbourne, Australia Blackwell Publishing Asia 01.08.2007
• Subjects: allergic eosinophilic airway inflammation; Aluminum Hydroxide; Animals; Anti-Asthmatic Agents - pharmacology; Anti-Asthmatic Agents - therapeutic use; Anti-Inflammatory Agents - pharmacology; Anti-Inflammatory Agents - therapeutic use; Asthma - immunology; Asthma - metabolism; Asthma - pathology; Asthma - prevention & control; bronchial asthma; Bronchoalveolar Lavage Fluid - chemistry; Bronchoalveolar Lavage Fluid - cytology; Disaccharides - pharmacology; Disaccharides - therapeutic use; Disease Models, Animal; Dose-Response Relationship, Drug; eosinophil; Eosinophils - drug effects; Eosinophils - immunology; Female; Flavanones - pharmacology; Flavanones - therapeutic use; flavonoid; IgE; Immunoglobulin E - blood; Inflammation - immunology; Inflammation - metabolism; Inflammation - pathology; Inflammation - prevention & control; interleukin-4; Interleukin-4 - metabolism; Interleukin-5 - metabolism; Leukocyte Count; Lung - drug effects; Lung - immunology; Lung - pathology; Mice; narirutin; Ovalbumin; Pulmonary Eosinophilia - immunology; Pulmonary Eosinophilia - metabolism; Pulmonary Eosinophilia - pathology; Pulmonary Eosinophilia - prevention & control
• ISSN: 0305-1870; 1440-1681
• DOI: 10.1111/j.1440-1681.2007.04636.x

SUMMARY 1 Flavonoids are naturally occurring compounds that possess anti‐allergic, anti‐inflammatory, antiproliferative and anti‐oxidant properties. In the present study, we investigated whether the flavonoid narirutin could reduce airway inflammation in ovalbumin (OVA)‐sensitized/challenged NC/Nga mice, a model of allergic eosinophilic airway inflammation. 2 Mice were initially immunized intraperitoneally with OVA on Days 0 and 7 and then challenged with inhaled OVA on Days 14, 15 and 16. In addition, some mice received narirutin orally at doses of 0.1, 1 or 10 mg/kg bodyweight daily on Days 7–16. 3 At 10 mg/kg, but not 0.1 or 1 mg/kg, narirutin significantly diminished OVA‐induced airway inflammation caused by infiltration of lung tissue with inflammatory and mucus‐producing cells, as well as reduced eosinophil counts in the peripheral blood and bronchoalveolar lavage fluid (BALF), interleukin (IL)‐4 levels in BALF and IgE levels in serum. 4 The mechanism of the anti‐inflammatory effect of narirutin are likely to be associated with a reduction in the OVA‐induced increases of IL‐4 and IgE in a murine model of allergic eosinophilic airway inflammation. These findings suggest that narirutin may be an effective new tool in the treatment of bronchial asthma.